T Cells Derived From Human Melanoma Draining Lymph Nodes Mediate Melanoma-specific Antitumor Responses In Vitro and In Vivo in Human Melanoma Xenograft Model-Reference-Cited by-同舟云学术

T Cells Derived From Human Melanoma Draining Lymph Nodes Mediate Melanoma-specific Antitumor Responses In Vitro and In Vivo in Human Melanoma Xenograft Model

Published:2015-07 Issue:6 Volume:38 Page:229-238
ISSN:1524-9557
Container-title:Journal of Immunotherapy
language:en
Short-container-title:

Author:

Zhang Mei,Graor Hallie,Visioni Anthony,Strohl Madeleine,Yan Lu,Caja Kevin,Kim Julian A.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology,Immunology,Immunology and Allergy

Reference17 articles.

1. Adoptive T cell therapy for cancer in the clinic.;June;J Clin Invest,2007

2. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.;Rosenberg;Clin Cancer Res,2011

3. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.;Spiess;J Natl Cancer Inst,1987

4. T-cell priming by dendriticells in lymph nodes occurs in three distinct phases.;Mempel;Nature,2004

5. In vivo antitumor efficacy of tumor-draining lymph node cells activated with nonspecific T-cell reagents.;Shu;J Immunother Emphasis Tumor Immunol,1993

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BG34-200 Immunotherapy of Advanced Melanoma;Cancers;2022-11-30

2. Kunitz type protease inhibitor from the canine tapeworm as a potential therapeutic for melanoma;Scientific Reports;2019-11-07

3. Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis;Journal for ImmunoTherapy of Cancer;2018-05-18

4. Theory and Practice of Immunotherapy Directed against the PRAME Antigen;Clinical oncohematology;2018

5. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression;Cancer Immunology, Immunotherapy;2017-09-13